Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib Phase 2b in Moderate to Severe Atopic Dermatitis
NCT02925117Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Percent Change From Baseline in Eczema Area and Severity Index Score at 16 weeks. Started Oct 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02925117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925117.